Triple negative breast cancer (TNBC) is most aggressive subtype of breast cancers with high
probability of metastasis as well as lack of specific targets and targeted therapeutics. TNBC …

Triple-negative breast cancer (TNBC) cells are deficient in estrogen, progesterone and
ERBB2 receptor expression, presenting a particularly challenging therapeutic target due to …

Triple negative breast cancer (TNBC) has a negative expression of estrogen receptors (ER),
progesterone receptors (PR), and human epidermal growth factor receptors (HER2). The …

Triple-negative breast cancer (TNBC) is a kind of breast cancer that lacks estrogen,
progesterone, and human epidermal growth factor receptor 2. This cancer is responsible for …

Large-scale genomic studies have identified multiple somatic aberrations in breast cancer,
including copy number alterations and point mutations. Still, identifying causal variants and …

Breast cancer is the most common type of cancer found in women and today represents a
significant challenge to public health. With the latest breakthroughs in molecular biology and …

Triple-negative breast cancer (TNBC), characterized by the absence or low expression of
estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor …

The epidermal growth factor receptor (EGFR) is the prototypical member of a family of
membrane-associated intrinsic tyrosine kinase receptors, the ErbB family. EGFR is activated …

Triplenegative breast cancer (TNBC) is a subgroup of 15%20% of diagnosed breast
cancer patients. It is generally considered to be the most difficult breast cancer subtype to …

The penetration of biological membranes is a prime obstacle for the delivery of
pharmaceutical drugs. Cell-penetrating peptide (CPP) is an efficient vehicle that can deliver …